

DesirÃ©e Hao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8007714/publications.pdf>

Version: 2024-02-01

62
papers

1,313
citations

304743
22
h-index

361022
35
g-index

63
all docs

63
docs citations

63
times ranked

2370
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. <i>Current Oncology</i> , 2022, 29, 1967-1982.	2.2	1
2	TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report. <i>Current Oncology</i> , 2022, 29, 3933-3939.	2.2	8
3	Piloting virtual mentorship: Evaluating acceptability and influence on wellness and professional identity in medical oncology (MO).. <i>Journal of Clinical Oncology</i> , 2022, 40, 11022-11022.	1.6	0
4	Canadian medical oncology workforce and cancer incidence trends: Supply and proxy demand analyses from 1994 to 2020.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13526-e13526.	1.6	0
5	Patient and caregiver-reported acceptability of an automatic phone call offering supportive and palliative care referral for advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24097-e24097.	1.6	0
6	Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland. <i>Clinical and Investigative Medicine</i> , 2021, 44, E38-41.	0.6	11
7	Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100157.	1.1	7
8	Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy. <i>Cancers</i> , 2020, 12, 1926.	3.7	7
9	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. <i>Future Oncology</i> , 2020, 16, 2799-2808.	2.4	50
10	The Gut Microbiota: A Potential Gateway to Improved Health Outcomes in Breast Cancer Treatment and Survivorship. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9239.	4.1	29
11	Intraparenchymal epithelioid malignant mesothelioma: A case report. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 61-63.	0.5	0
12	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	2.0	19
13	Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3546-3546.	1.6	3
14	Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosisâ€”a Canadian trial in progress. , 2020, , .		0
15	Abstract PO-029: Operationalizing a prioritized COVID-19 testing strategy at a Canadian tertiary care cancer center. , 2020, , .		0
16	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019, 15, 2905-2914.	2.4	71
17	MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study. <i>Diagnostic Pathology</i> , 2019, 14, 78.	2.0	7
18	Impact of Asian ethnicity on outcome in metastatic EGFRâ€”mutant nonâ€”small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 343-352.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. <i>Lung Cancer</i> , 2018, 120, 142-148.	2.0	37
20	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874.	2.4	90
21	Abstract A89: Gender and racial disparities in non-small cell lung cancer: A systematic review. , 2018, , .		0
22	A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. <i>Lung Cancer</i> , 2017, 104, 65-69.	2.0	19
23	MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. <i>Journal of Thoracic Oncology</i> , 2017, 12, S392-S393.	1.1	12
24	Paraneoplastic neuropsychiatric syndrome presenting as delirium. <i>BMJ Supportive and Palliative Care</i> , 2017, 7, 218-220.	1.6	4
25	Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. <i>Cmaj</i> , 2017, 189, E1030-E1040.	2.0	40
26	Distress levels in patients with oropharyngeal vs. non-oropharyngeal squamous cell carcinomas of the head and neck over 1 year after diagnosis: a retrospective cohort study. <i>Supportive Care in Cancer</i> , 2017, 25, 3225-3233.	2.2	9
27	Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3058-3058.	1.6	2
28	Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC. <i>Oncotarget</i> , 2017, 8, 38326-38336.	1.8	22
29	ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent. <i>Head and Neck</i> , 2016, 38, E384-91.	2.0	8
30	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 810-815.	1.6	79
31	Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment. <i>Metabolomics</i> , 2016, 12, 58.	3.0	47
32	Secondary Neuroendocrine Carcinoma Following High-Dose Radiotherapy for Head and Neck Cancer: Report of Two Cases. <i>Cureus</i> , 2016, 8, e847.	0.5	4
33	Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study. <i>CMAJ Open</i> , 2014, 2, E127-E132.	2.4	27
34	Dose Delivery Analysis of Weekly Versus 3-Weekly Cisplatin Concurrent With Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 63-69.	1.3	21
35	Pan-Canadian rash trial with EGFR inhibitors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8013-8013.	1.6	3
36	Evaluation of E-cadherin, β -catenin and vimentin protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients. <i>Clinical and Investigative Medicine</i> , 2014, 37, 320.	0.6	12

#	ARTICLE	IF	CITATIONS
37	Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1340-1345.	0.8	11
38	Abstract 3545: ATM, TS and RRM1 protein expression in nasopharyngeal carcinomas (NPC) treated with curative intent.. , 2013, , .		0
39	An analysis of the temporal, age, and gender trends in human papillomavirus virus (HPV)-related versus non-HPV-related head and neck cancers (HNC) in Alberta, Canada.. Journal of Clinical Oncology, 2013, 31, e12505-e12505.	1.6	0
40	Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 579-586.	1.1	74
41	Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head and Neck, 2012, 34, 785-791.	2.0	17
42	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2012, 69, 815-824.	2.3	6
43	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 563-571.	2.3	16
44	A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.. Journal of Clinical Oncology, 2012, 30, 3013-3013.	1.6	5
45	CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1169-1178.	1.1	60
46	Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head and Neck, 2011, 33, 251-256.	2.0	35
47	High Stromal Carbonic Anhydrase IX Expression Is Associated With Decreased Survival in p16-Negative Head-and-Neck Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 80, 249-257.	0.8	37
48	Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiotherapy and Oncology, 2010, 97, 352-359.	0.6	33
49	Abstract 1742: Evaluating the prognostic value of EGFR by p16/HPV status in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiation. , 2010, , .		0
50	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2009, 65, 167-175.	2.3	2
51	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemotherapy and Pharmacology, 2008, 62, 911-919.	2.3	37
52	P2-241: A retrospective study of the role of chemotherapy in non-small cell lung cancer (nscle) patients with brain metastases treated in Alberta, Canada from 2000-2004. Journal of Thoracic Oncology, 2007, 2, S668-S669.	1.1	0
53	B1-02: A Phase 1-2 study of the anti-sense oligonucleotide OGX-011 in combination with a platinum/gemcitabine regimen as first-line therapy for advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S333.	1.1	0
54	P3-125: Similar characteristics of responders treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) Gefitinib and Erlotinib for advanced non small cell lung cancer (NSCLC) in a single Canadian institution.. Journal of Thoracic Oncology, 2007, 2, S732.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Platinum-Based Concurrent Chemoradiotherapy for Tumors of the Head and Neck and the Esophagus. <i>Seminars in Radiation Oncology</i> , 2006, 16, 10-19.	2.2	23
56	Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. <i>Head and Neck</i> , 2006, 28, 189-196.	2.0	24
57	Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2006, 24, 190-205.	1.6	108
58	Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2052-2058.	1.6	49
59	Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6345-6350.	7.0	48
60	Inhibiting Signal Transduction: Recent Advances in the Development of Receptor Tyrosine Kinase and Ras Inhibitors. <i>Cancer Investigation</i> , 2002, 20, 387-404.	1.3	31
61	Promising Developments in Targeted Therapies for non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 4, 111-123.	2.6	3
62	Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642). <i>Investigational New Drugs</i> , 2002, 20, 261-270.	2.6	32